ANTITUMOR EFFECT IN VIVO OF THE NEW PYRIDINE COMPOUND

Abstract

Abstract. The study was the antitumor activity of a new compound - a pyridine derivative (LHT-13-19). On the culture of human colon cancer HCT116, the suppressive concentration of LHT-13-19 was determined during incubation of tumor cells in the concentration range from 10-9 to 10-7 M. The survival of tumor cells was also determined in the MTT test. Antitumor activity in vivo was studied on thirty athymic humanized 12-week-old female mice of the BALB / c nu / nu line with xenograft adenocarcinoma of the large intestine, divided into 3 groups, 10 mice each, which received intraperitoneal injections of 0.9% sodium chloride solution in a volume of 0.5 ml, cyclophosphamide at a dose of 10 mg / kg, LHT-13-19 at a daily dose of 3.7 mg / kg, respectively, for 10 days. Daily incubation of human colon tumor cells with LHT-13-19 is accompanied by the formation of the cytotoxic effect of the compound. In a xenograft model of colon adenocarcinoma, 10-day intraperitoneal administration of compound LHT-13-19 at a daily dose of 3.7 mg / kg was accompanied by the formation of an antitumor effect in the form of an increase in the doubling time of the tumor size, the survival rate of animals - carriers of xenograft, and a decrease in the frequency of metastasis. Keywords. Pyridine derivatives, LHT-13-19, cell culture, anticancer activity, inhibitory concentration